RETREG1 and hepatocellular carcinoma: The results of the present study showed that FAM134B was overexpressed in 62% (n = 50) of HCC patients as well as 45.9% (56/122) of HCC tumor tissue microarray, which was associated with increased tumor size (P = 0.025), pathological vascular invasion (P = 0.026), lower differentiation grade (P = 0.023), cancer recurrence (P = 0.044) and portal vein tumor thrombus (P = 0.036) in HCC.